Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Paris – page 91

2 598 clinical trials in Paris, France across 36 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Paris at a glance
2 598
clinical trials
  • Research sites36
Type of trial
Recruitment status
Quick filters

2 598 trials in Paris

Open in trial search

Idiopathic pulmonary fibrosis

Not yet recruiting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Small cell lung cancer limited stage

Not yet recruiting

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Pharmacosmos A/S

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Autoimmune hepatitis

Not yet recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Epilepsy

Not yet recruiting

Efficacy of fluoxetine added to standard anti‑seizure therapy in children aged 8 years and older with drug‑resistant complex and rare epilepsy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fluoxetine
  • Sponsor:Centre Hospitalier Regional De Marseille

Colorectal cancer metastatic

Not yet recruiting

Second‑line ivonescimab plus chemotherapy drug combination versus bevacizumab in patients with metastatic colorectal cancer without liver metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Unicancer

Asthma

Not yet recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Sjogren's syndrome

Not yet recruiting

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colon cancer+3

Not yet recruiting

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Abemaciclib
  • Sponsor:Institut Gustave Roussy

Embolism venous

Not yet recruiting

Safety, Tolerability and Effect of RBD4059 Injection in Adults with Prior VTE After Anticoagulant Therapy and Cancer Patients at High Risk of VTE

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rbd4059
  • Sponsor:Ribocure Pharmaceuticals AB

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Paris

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma and endometrial cancer, evaluating innovative treatment combinations and survival outcomes.

  • Advanced cancer therapies
  • Combination treatments
  • Survival outcome assessment
02 Metabolic Disorders

Clinical investigations targeting Type 1 Diabetes and obesity, with novel therapeutic approaches using tirzepatide for improved glycemic control.

  • Diabetes management
  • Weight control
  • Metabolic health
03 Infectious Diseases

Innovative vaccine trials for COVID-19, influenza, and cytomegalovirus, exploring both intranasal and injectable delivery methods.

  • Vaccine development
  • Immunogenicity studies
  • Prevention strategies
04 Neurological Conditions

Advanced research in multiple sclerosis and Alzheimer's disease, utilizing cutting-edge imaging techniques to study neuroinflammation and synaptic density.

  • Brain imaging
  • Neurodegenerative diseases
  • Disease progression
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.